-
Cureus Nov 2023Ameloblastoma is a benign yet locally aggressive tumor of the jaw bones and is most commonly found in the lower mandibular region. Histologically, it shows benign...
Ameloblastoma is a benign yet locally aggressive tumor of the jaw bones and is most commonly found in the lower mandibular region. Histologically, it shows benign characteristics. However, ameloblastoma can turn malignant to show a more aggressive clinical course. Carcinoma ex ameloblastoma is an extremely rare malignancy arising from a pre-existing long-standing ameloblastoma or a recurrence of an ameloblastoma. According to the literature search, six to seven cases have so far been documented, and the majority of the lesions had a propensity to metastasize. Here, we present a case of carcinoma ex ameloblastoma implicating a 19-year-old male patient manifesting in the mandible, which arises from pre-existing ameloblastoma.
PubMed: 38156168
DOI: 10.7759/cureus.49536 -
Case Reports in Dentistry 2024Peripheral ameloblastic carcinoma is an extremely rare odontogenic carcinoma. Its histopathological feature is identical to the intraosseous type. This case report...
Peripheral ameloblastic carcinoma is an extremely rare odontogenic carcinoma. Its histopathological feature is identical to the intraosseous type. This case report details a case of peripheral ameloblastic carcinoma at the right posterior maxilla region in a 60-year-old Thai male. The patient underwent a definitive treatment by partial maxillectomy and reconstruction with buccal fat pad. After 1-year follow-up, no recurrence of the lesion was found.
PubMed: 38229833
DOI: 10.1155/2024/4289276 -
Annals of Maxillofacial Surgery 2023Ameloblastic carcinoma is defined as an ameloblastoma in which there is histological evidence of malignancy in primary tumour or recurrent tumour regardless if it has...
RATIONALE
Ameloblastic carcinoma is defined as an ameloblastoma in which there is histological evidence of malignancy in primary tumour or recurrent tumour regardless if it has metastasised or not. It is aggressive in nature.
PATIENT CONCERNS
The patient presented with a painful swelling associated with restricted mouth opening.
DIAGNOSIS
This is the clinical profile of a patient who has presented with a recurrent ameloblastic carcinoma.
TREATMENT
Histological features of the excised specimen resemble ameloblastic carcinoma constituting cytological atypia with tall columnar cells.
OUTCOME
Excision of tumour was done. Reconstruction was done using pectoralis major myocutaneous flap.
TAKE-AWAY LESSONS
Ameloblastic carcinoma is an aggressive tumour and constitutes destruction and distant metastatic spread. Hence, aggressive resection is the choice of treatment along with a long-term follow-up for better quality of life.
PubMed: 38405565
DOI: 10.4103/ams.ams_66_23 -
Pathology International Aug 2023Ghost cell odontogenic carcinoma (GCOC) is an extremely rare intraosseous malignant odontogenic tumor with prominent ghost cell keratinization and dentinoid formation....
Ghost cell odontogenic carcinoma (GCOC) is an extremely rare intraosseous malignant odontogenic tumor with prominent ghost cell keratinization and dentinoid formation. Here, we present the first case of GCOC arising in dentinogenic ghost cell tumor (DGCT), peripheral. The patient was a man in his 60s with an exophytic mass in the anterior part of lower gingiva. The resected tumor measured 4.5 cm in maximum diameter. Histologically, the nonencapsulated tumor proliferated in the gingiva without bone invasion. It was predominantly composed of ameloblastoma-like nests and islands of basaloid cells with ghost cells and dentinoid in the mature connective tissue, suggesting DGCT, peripheral. As minor components, sheets of atypical basaloid cells and ameloblastic carcinoma-like nests with pleomorphism and high proliferative activity (Ki-67 labeling index up to 40%) consistent with malignancy were identified. CTNNB1 mutation and β-catenin nuclear translocation were observed in both benign and malignant components. Final diagnosis was GCOC arising in DGCT, peripheral. GCOC shows similar histological features to DGCT. In this unique case without invasion, the cytological atypia and high proliferative activity supports the diagnosis of malignant transformation from DGCT.
Topics: Male; Humans; Odontogenic Tumors; Jaw Neoplasms; Ameloblastoma; Cell Transformation, Neoplastic; Carcinoma
PubMed: 37401869
DOI: 10.1111/pin.13351 -
Oral Oncology Mar 2024
Topics: Humans; Ameloblastoma; Odontogenic Tumors; Mandibular Neoplasms; Carcinoma
PubMed: 38271776
DOI: 10.1016/j.oraloncology.2024.106704 -
Oral Oncology Jan 2024Ameloblastoma is characterized by aggressive nature, high recurrence rate, occasional malignant transformation, but recurrence and malignant incidence of ameloblastoma...
BACKGROUND
Ameloblastoma is characterized by aggressive nature, high recurrence rate, occasional malignant transformation, but recurrence and malignant incidence of ameloblastoma are not yet addressed by a large-scale case series study.
MATERIALS AND METHODS
This study provided a detailed description of the relationship between demographic characteristics and recurrence and malignant cases with different clinical types of ameloblastoma (n = 1626).
RESULTS
The overall incidence of recurrence and malignancy was 17.2 % and 3.4 %, respectively. Notably, we observed that there were multiple recurrent episodes (mean time, 24.3-28.7 months) among ameloblastoma patients. Multivariate analysis revealed that age of > 45 years (odds ratios (OR), 2.10; 95 % confidence interval (CI), 1.17-3.76), male (OR, 3.24; 95 %CI, 1.49-6.99), maxilla (OR, 5.58; 95 %CI, 3.11-10.0), and pre-existing recurrence (OR, 3.79; 95 %CI, 2.05-7.01) as independent factors were associated significantly with increased risk of malignancy.
CONCLUSION
Identification of the clinical factors responsible for increased risk of malignancy provides better insight in management planning for ameloblastoma.
Topics: Humans; Male; Middle Aged; Ameloblastoma; Maxilla; China; Cell Transformation, Neoplastic; Demography
PubMed: 38061123
DOI: 10.1016/j.oraloncology.2023.106651 -
Expression of Calretinin Expression in Odontogenic Cysts and Odontogenic Tumors - Original Research.Journal of Pharmacy & Bioallied Sciences Feb 2024The present study was conducted for assessing variability in calretinin expression among odontogenic cysts as well as tumor cases.
AIM
The present study was conducted for assessing variability in calretinin expression among odontogenic cysts as well as tumor cases.
MATERIALS AND METHODS
Fifteen cases were included in the present research consisting of cases like - dentigerous cyst, odontogenic keratocyst, apical radicular cyst along with tumors like ameloblastoma, ameloblastic carcinoma, adenomatoid odontogenic tumor. Calretinin antibody was used for immunohistochemical staining. The amount of expression of this calretinin was statistically analyzed with the help of Chi-square test where < 0.05 was considered noteworthy statistically.
RESULTS
Most cases of ameloblastomas were highly positive for calretinin expression as compared to other cysts and tumors. Therefore, the correlation of this variation of expression of calretinin was statistically noteworthy ( = 0.00).
CONCLUSION
In this study, we concluded that for ameloblastomas, calretinin can be a specific marker immunohistochemically and can help in identifying the amount of aggressive spread of various odontogenic tumors.
PubMed: 38595345
DOI: 10.4103/jpbs.jpbs_469_23 -
Journal of Oral Pathology & Medicine :... Mar 2024Despite recent advances in the use of immune checkpoint blockade (ICB) across various cancer types, its efficacy in odontogenic carcinomas remains unexplored. This study...
BACKGROUND
Despite recent advances in the use of immune checkpoint blockade (ICB) across various cancer types, its efficacy in odontogenic carcinomas remains unexplored. This study aims to investigate PD-L1 expression and the tumor immune microenvironment (TIME) in odontogenic carcinomas to determine the therapeutic potential of ICB and the significance of immune markers.
METHODS
The expressions of PD-L1 and T cell markers (CD3, CD8, and FOXP3) were visualized by immunohistochemistry in 21 tissue samples of odontogenic carcinomas. Tumoral PD-L1 expression and the density and spatial distribution of T cell subsets were evaluated, from which TIME was determined. The associations of the variables with clinicopathological and prognostic factors were statistically analyzed.
RESULTS
PD-L1 was positively expressed in 52.4% (11/21) of the cases studied. Among tumor types, ameloblastic carcinoma showed significantly higher PD-L1 expression (p = 0.016). TIME based on the intratumoral and stromal T cell distribution was immune-inflamed in 61.9% (13/21) and immune-excluded in 38.1% (8/21), with no immune-desert cases. PD-L1 expression was associated with the densities of all intratumoral T cell subsets (p = 0.03 for CD3, p = 0.03 for CD8, and p = 0.008 for FOXP3) but not with those of stromal T cells. High PD-L1 expression was associated with larger tumor size (p = 0.021), while the intratumoral CD8/CD3 ratio was inversely correlated with tumor size (p = 0.048).
CONCLUSION
These findings indicate the involvement of adaptive immune resistance in a subset of odontogenic carcinomas and support the therapeutic potential of ICB in patients with these rare malignancies.
Topics: Humans; B7-H1 Antigen; Immune Checkpoint Inhibitors; T-Lymphocytes; Mouth Neoplasms; Odontogenic Tumors; Forkhead Transcription Factors; Carcinoma; Tumor Microenvironment; CD8-Positive T-Lymphocytes; Biomarkers, Tumor
PubMed: 38449350
DOI: 10.1111/jop.13525 -
Orphanet Journal of Rare Diseases Feb 2024Rare diseases present immense challenges to physicians, patients, and the healthcare system at large due to a scarcity of research and knowledge in the field. This...
Rare diseases present immense challenges to physicians, patients, and the healthcare system at large due to a scarcity of research and knowledge in the field. This contributes to uncertainty surrounding rare diseases, which can hinder the management of these chronic conditions. An analysis of my family's experience battling my mother's ameloblastic carcinoma highlights the difficulties in communicating the uncertainty around rare diseases and their damaging effects on our family's well-being. Here, we will recognize the importance of acknowledging uncertainty during diagnoses and advocating for enhanced detection strategies. The goal of this article is to emphasize that effective medical communication around rare diseases, accessibility to accurate information, proper services, and a shift toward a culture that prioritizes patient well-being are critical for improving health outcomes for rare disease patients.
Topics: Humans; Uncertainty; Rare Diseases; Family; Communication; Delivery of Health Care
PubMed: 38403651
DOI: 10.1186/s13023-024-03050-y -
Frontiers in Oncology 2024Since 1964, there has been a scarcity of reported cases of primary ameloblastoma (AM) or ameloblastic carcinoma (AMCa) of the skull. The clinical presentation and...
BACKGROUND
Since 1964, there has been a scarcity of reported cases of primary ameloblastoma (AM) or ameloblastic carcinoma (AMCa) of the skull. The clinical presentation and distinctive features of this uncommon condition at specific anatomical sites remain unclear. We report a case of malignant transformation of a primary AM of the skull situated in the frontal-temporal-parietal region and highlight its similarities to other cases reported in the literature.
CLINICAL PRESENTATION
A 53-year-old female patient presented with a 20-day history of headaches and bilateral lower limb weakness for 10 days. Physical examination revealed slow and unsteady gait. An occupying lesion was observed in the right frontal-temporal-parietal region of the skull on the Cranial imaging. A right cranial bone tumor margin expansion resection was performed. The patient's motor functions recovered normally after surgery. Postoperative imaging examinations showed10 tumor resection. Follow-up imaging examinations showed tumor recurrence. The patient underwent resection of the recurrent tumor. Postoperative pathological analysis revealed malignant transformation of the AM.Follow-up imaging examinations showed tumor recurrence again. The patient was admitted for stereotactic radiotherapy. Follow-up imaging examinations demonstrated no evidence of tumor recurrence and subsequent chest CT revealed no signs of metastasis.
CONCLUSION
Primary AM or AMCa of the skull is increasingly being described in the literature, but detailed reports on the malignant transformation of primary AM of the skull are lacking. The pathogenesis of this condition remains unclear. Aggressive treatment and close follow-up may be crucial for preventing disease recurrence and malignant transformation.
PubMed: 38577340
DOI: 10.3389/fonc.2024.1365625